EU Market Access Europe marketing authorization positions Atara as a pioneer in off the shelf allogeneic T cell therapies for EBV driven diseases. Target European hospitals, transplant centers and specialty clinics with tab cel and future therapies. Initiate distributor partnerships and early payer engagements to secure reimbursement and enable rapid patient access across EU markets.

Platform Synergy A unified EBV T cell platform enables cross selling across EBV driven diseases and future CAR T and TCR therapies. This creates opportunities to engage large oncology and transplant networks with bundled adoption plans, training and inventory programs.

Supply Chain Readiness Manufacturing issues highlight a need for robust supply chain partnerships. Position as a partner for contract manufacturers and health systems to improve consistency and regulatory readiness for on time delivery of off the shelf therapies.

Evidence Driven Strong data capabilities with Power BI and AWS enable real world evidence and outcomes dashboards. Propose collaborations with hospitals, payers and patient groups to support value based pricing and reimbursement discussions for EBV T cell therapies.

Competitive Positioning Atara is positioned as the most advanced allogeneic T cell immunotherapy company with European market authorization for off the shelf products. Engage large health systems and payers with clear benefits of rapid patient access, simplified logistics, and potential cost savings versus personalized therapies.